Kathryn Lumb
About Kathryn Lumb
Kathryn Lumb is the Vice President Business Development Counsel at Alkermes in the Greater Cambridge Area, with over 20 years of experience in strategic transactions and intellectual property law in the biopharmaceutical industry.
Title
Kathryn Lumb is currently serving as Vice President Business Development Counsel at Alkermes in the Greater Cambridge Area.
Company
Kathryn Lumb is associated with Alkermes, where she holds the position of Vice President Business Development Counsel. Alkermes is a biopharmaceutical company focused on developing innovative medicines in various therapeutic areas.
Past Roles at Law Firms
Kathryn Lumb has extensive experience working in prominent law firms, including Kenyon & Kenyon LLP and Leydig, Voit & Mayer, Ltd. She held the position of Associate at Kenyon & Kenyon LLP from 2000 to 2004 in the Greater New York City Area and at Leydig, Voit & Mayer, Ltd. from 1998 to 2000 in the Greater Chicago Area.
Former In-House Counsel Positions
Kathryn Lumb has a robust background in in-house legal roles within the biopharmaceutical sector. She served as Assistant General Counsel at Pfizer (formerly Wyeth) from 2010 to 2012 and at Elan Pharmaceuticals from 2012 to 2014. Earlier, she was Patent Counsel at Wyeth from 2006 to 2009 and Senior Patent Attorney from 2004 to 2006.
Founder of Northeast Intellectual Property
Kathryn Lumb founded Northeast Intellectual Property in 2015 and led the firm until 2019. The firm specialized in intellectual property law, offering expert legal strategies for businesses in the biopharmaceutical industry.
Educational Background
Kathryn Lumb holds a JD from The George Washington University Law School, earned between 1995 and 1998. Additionally, she attained a BS in Molecular Biology from Lehigh University, demonstrating her combined expertise in both scientific and legal fields.
Experience in Strategic Transactions and Intellectual Property
With over 20 years of experience, Kathryn Lumb focuses on strategic transactions and intellectual property-related legal issues in the biopharmaceutical industry. She specializes in providing business-oriented legal strategies and has held multiple senior legal positions in leading pharmaceutical companies.